Table 1.
Pre-implementation slope, % (95% CI) | Implementation period sudden change in level, % (95% CI) | Change in slope pre- and post- implementation, % (95% CI) | 6 month level effect, % (95% CI) | 12 month level effect, % (95% CI) | 24 month level effect, % (95% CI) | ||
---|---|---|---|---|---|---|---|
Medicine | compliance with policy/approval by infection team | 0.79 (−0.78 to 2.36) | 6.48 (−1.25 to 14.20) | −1.77 (−6.36–2.82) | 4.70 (−3.55–12.96) | 2.93 (−7.96 to 13.83) | −0.61 (−19.21 to 18.00) |
documentation of stop/review date | 3.57 (−6.99 to 14.12) | 15.20 (−17.81 to 48.22) | 1.69 (−13.27 to 16.66) | 16.90 (−23.39 to 57.18) | 21.22 (−46.54 to 88.98) | 21.98 (−54.88 to 98.84) | |
documentation of indication | 13.83 (10.89–16.77)** | −16.25 (−42.52 to 10.01) | −15.32 (−22.88 to − 7.77)** | −31.58 (−53.55 to − 9.60)** | −46.90 (−66.65 to − 27.14)** | −77.55 (−100.94 to − 54.15)** | |
Surgery | compliance with policy/approval by infection team | 0.21 (−1.29 to 1.71) | 6.63 (0.15 to 13.10)* | 0.084 (−3.15 to 3.31) | 6.71 (−0.06 to 13.48) | 6.80 (−1.60–15.20) | 6.96 (−6.55–20.48) |
documentation of stop/review date | 1.15 (−10.62 to 12.92) | 35.97 (−3.72 to 75.66) | 0.36 (−11.94 to 12.67) | 36.33 (−13.96 to 86.63) | 36.70 (−24.84 to 98.24) | 37.43 (−47.49 to 122.34) | |
documentation of indication | 15.71 (8.16–23.25)** | −14.62 (−42.88 to 13.63) | −19.31 (−30.38 to − 8.24)** | −33.93 (−65.37 to − 2.50)* | −53.24 (−90.97 to − 15.52)** | −91.86 (−146.90 to − 36.83)** |
P < 0.05. **P < 0.01.